



View and print projects of report number LMDB0014

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
33101	2024-02-12	Samfenet (KR); trastuzumab-dttb; SB3; SB-3	Her2 inhibitor	Rec humanized mab, biosimilar of Herceptin (trastuzumab)	Antibody	Samsung Bioepis (originator, subsidiary of Samsung Biologics)	Korea, Republic of	Oncology	Metastatic breast cancer	Market	
33100	2024-02-12	Remaloce (KR); SB2; infliximab biosimilar	Tumor necrosis factor (TNF) alpha antagonist	Rec chimeric mab. Biosimilar of Remicade (infliximab)	Antibody	Samsung Bioepis (originator, subsidiary of Samsung Biologics)	Korea, Republic of	Rheumatoid & autoimmune	Rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.	Market	
33099	2024-02-12	bHumira (US) / Adalocce (KR); adalimumab-bwwd; SB5	Tumor necrosis factor (TNF) inhibitor	Rec fully human mab. Biosimilar of Humira (adalimumab)	Antibody	Samsung Bioepis (subsidiary of Samsung Biologics)	Korea, Republic of	Rheumatoid & autoimmune	Rheumatoid arthritis and other inflammatory diseases	Market	
32822	2024-03-03	Adalimumab BS "CTNK" ; adalimumab- aaty; CT-P17 (Japan development)	TNF alpha antagonist	Rec fully human mab. Biosimilar of adalimumab (Humira) from AbbVie. High- concentration formulation: SC with auto-injector	Antibody	Nippon Kayaku (JP rights from Celltrion)	Japan	Rheumatoid & autoimmune	Rheumatoid arthritis	Market	
32633	2024-02-28	Vyvgart; efgartigimod alfa-fcab; ARGX-113 (China Development)	Increased affinity to neonatal Fc receptor (FcRn): to clear and degrade circulating disease- causing autoantibodies	Rec human ABDEG- mutated IgG1 Fc- fragment of Ig antibody (from llamas) in IV formulation	Antibody	Zai Lab (China rights from Argenx)	China	Neurology & psychiatry	Generalized myasthenia gravis (gMG) (ADAPT+ trial)	Market	
32482	2024-02-12	Amelivu (KR); ranibizumab-nuna; SB11; SB-11	Vascular endothelial growth factor (VEGF) inhibitor	Rec humanized Fab for intravitreal injection (biosimilar of Lucentis)	Antibody	Samsung Bioepis (originator, subsidiary of Samsung Biologics)	Korea, Republic of	Ophthalmology & otorhinolaryngology	Wet age-related macular degeneration (AMD)	Market	

Search among projects of report number LMDB0014

Print Export project list
 Export project list

Search Clear

Any Word
 All Words
 Exact Phrase
 Advanced Search

Target:

Technology:

- Territory**
- All Countries
 - Aaland Islands
 - Afghanistan
 - Albania
 - Algeria
 - American Samoa
 - Andorra
 - Angola

- Category**
- All Categories
 - Antibody
 - Cells

- Therapeutic Area**
- All Therapeutic Areas
 - Cardiovascular, blood & acute care
 - Dermatology

- Phase**
- All Phases
 - Market
 - sBLA

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase
----	-------------	---------	--------	-------------------	----------	---------	-----------	------------------	------------	-------

Projects 0 to 0 of 0

Search among projects of report number L

Remicade

 Any Word All Words Exact Phrase Advanced Search
 Target:
 Technology:

Id	Last Update	Project	Target
33100	2024-02-12	Remaloce (KR); SB2; infliximab biosimilar	Tumor necrosis factor (TNF) antagonist
27082	2024-02-07	Infliximab BS "NK" for I.V. Infusion 100m (JP); infliximab-dyyb; CT-P13 (Japan market)	Tumor necrosis factor (TNF) antagonist

View Project [6587]

Print

Last Update: 2024-02-16

Remicade; infliximab
Target: TNF alpha antagonist
Class of Compound: Rec chimeric IgG1 mab
Category: Antibody
Company: Janssen (Johnson & Johnson, J&J) & Merck & Co. (acquired Schering-Plough) & Mitsubishi Tanabe Pharma
Territory: United States / Japan
Therapeutic Area: Rheumatoid & autoimmune
Indication: Moderately to severely active rheumatoid arthritis
Phase: Market

Administration:
Drug Delivery:
Status: Active
Approval US: Approved
Approval UE: Approved
Approval RoW: Approved in Japan in 2002
Antibody Tech:
Protein Tech:
DNA Tech:
RNA Tech:
Cell Tech:
Vaccine Tech:
Partnering:

Date	Title	News	Comments
2024-02-16	J&J PR Jan 23, 2024		2023 sales in J&J territories of US\$ 1,839 mln (-21.5% vs 2022); 2023 sales in Merck territories of US\$ 187 mln (-9% vs 2022) (source); calendar year 2023 sales in JP of JPY 30.9 bln (-14.2% vs 022) = US\$ 210 mln (source) - Total 2023 sales of US\$ 2,236 mln (-20.9% vs 2022)
2023-02-09	J&J SEC Form 8-K Jan 24, 2023		2022 sales in J&J territories of US\$ 2,343 mln (-26.6% vs previous year); 2022 sales in Merck territories of US\$ 207 mln (-31% vs previous year) (source); calendar year 2022 sales in MTP territory of Yen 36 bln = US\$ 277 mln (source). Total 2022 sales of US\$ 2,827 mln (-26.5% vs previous year)
2022-03-11	J&J 2021 Key Product Sales Jan 25, 2022		2021 sales in J&J territories of US\$ 3,190 mln (-14.9% vs 2020); Merck reported 2021 sales of US\$ 299 mln (-9% vs 2020) (source); calendar year 2021 sales in MTP territories of Yen 41.2 bln (-11.2% vs 2020) (source) = US\$ 358 mln. total 2021 sales of US\$ 3,847 mln
2021-02-08	J&J 2020 Key Product Sales Jan 26, 2021		2020 sales in J&J territories of US\$ 3,747 mln (-14.4% vs previous year); 2020 sales in Merck territories of US\$ 330 mln (-20% vs previous year) source ; calendar year 2020 sales in MTP territories of Yen 46.4 mln (-13.1% vs previous year) (source)

Dear Brutus,
 Your account will expire on March 31, 2024.
 Please contact us at support@pipelinereview.com

Print

Indication	Phase	
rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.	Market	
rheumatoid arthritis (J&J), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.	Market	



Prepare report from projects of report number LMDB0014

Date: to: Custom Report – by Category

Territory

- All Countries
- Aaland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

Target:

Technology:

- All Technologies

Category

- All Categories
- Antibody
- Cells

Therapeutic Area

- All Areas
- Cardiovascular, blood & acute care
- Dermatology

Phase

- All Phases
- Market
- sBLA

Keyword

- Any Word All Words Exact Phrase

Id	Project	Target	Class of Compound	Company	Category	Indication	R&D Stage	Message
33100	Remalocce (KR); SB2; infliximab biosimilar	Tumor necrosis factor (TNF) alpha antagonist	Rec chimeric mab. Biosimilar of Remicade (infliximab)	Samsung Bioepis (originator, subsidiary of Samsung Biologics)	Antibody	Rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.	Market	<p>Samsung Biologics Presentation Jan 24, 2024 -</p> <p>2023 revenues from biosimilar antibody franchise of KRW 1,020 bln (+8% vs 2022) = US\$ 764 mln.</p>
33099	bHumira (US) / Adalocce (KR): adalimumab-bwwd; SB5	Tumor necrosis factor (TNF) inhibitor	Rec fully human mab. Biosimilar of Humira (adalimumab)	Samsung Bioepis (subsidiary of Samsung Biologics)	Antibody	Rheumatoid arthritis and other inflammatory diseases	Market	<p>Samsung Biologics Presentation Jan 24, 2024 -</p> <p>In 2023, expansion of formulary coverage in US. 2023 revenues from biosimilar antibody franchise of KRW 1,020 bln (+8% vs 2022) = US\$ 764 mln.</p>
32822	Adalimumab BS "CTNK" ; adalimumab-aaty; CT-P17 (Japan development)	TNF alpha antagonist	Rec fully human mab. Biosimilar of adalimumab (Humira) from AbbVie. High-concentration	Nippon Kayaku (JP rights from Celltrion)	Antibody	Rheumatoid arthritis	Market	<p>Nippon Kayaku Presentation Feb 07, 2024 -</p> <p>Calendar year 2023 combined sales of trastuzumab,</p>